Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Manufacturers with strong cardiometabolic data and scalable production are likely to gain advantage as payers review access across diabetes and obesity indications. GLP-1 Receptor Agonist Market Value Analysis The GLP-1 receptor agonist market is moving from diabetes-centered prescribing toward broader cardiometabolic disease management
In particular, tell your provider if you have or have a past history of: Type 1 or type 2 diabetes Thyroid cancer Pancreatitis Kidney disease Diabetic retinopathy Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding
However, its biological concentration varies considerably
A 2023 study out of the University of British Columbia linked GLP-1 agonists to a heightened risk of severe gastrointestinal problems. These problems include gastroparesis, pancreatitis, and bowel obstruction
US$ 20.96
US$ 26.07
US$ 28.82
US$ 29.23
US$ 28.61
US$ 29.32
